Hemispherian AS

OSLO, Norway, Dec. 19, 2023 /PRNewswire/ -- Hemispherian AS ("Hemispherian" or the "Company"), a Norwegian preclinical pharmaceutical company focused on small molecule cancer therapeutics has been granted NOK 16 million by the Research Council of Norway. Hemispherian's proprietary GLIX compounds target a novel mechanism that is common to all cancers. The company's lead drug candidate, GLIX1, is in late-stage preclinical development for the treatment of glioblastoma, a highly aggressive and most common primary brain cancer, which continues to be one of the highest unmet needs in oncology. The funding awarded is earmarked for the development of Hemispherian's promising drug candidates aimed at treating platinum-resistant ovarian cancers, one of the most challenging gynecological malignancies. "We are immensely grateful for this support from the Research Council of Norway," said Zeno Albisser, CEO of Hemispherian. "Our team is excited to advance our second asset, GLIX5, towards clinical use. We are dedicated to developing therapies that will make a tangible difference in the lives of those battling cancer." About Hemispherian AS Hemispherian is an innovative pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX). GLIX compounds target the TET2 enzyme and activate the DNA damage response resulting in cancer cell death. The company's lead compound, GLIX1, is in late-stage preclinical development for the treatment of glioblastoma, a deadly cancer of the central nervous system and the leading cause of death by disease in children. Hemispherian's further advances GLIX5 for the treatment of platinum-resistant ovarian cancers. Hemispherian is based in Oslo, Norway. For more information, visit . Contact: Zeno Albisser, CEO Gaustadalléen 21 0349 Oslo zeno@hemispherian.com +47 406 03 455 SOURCE Hemispherian AS

OSLO, Norway , Nov. 24, 2022 /PRNewswire/ -- Hemispherian AS ("Hemispherian" or the "Company"), a Norwegian preclinical pharmaceutical company focused on small molecule cancer therapeutics targeting the DNA damage response, is delighted to announce the closure of the first tranche of its series A1 financing round. The round raised NOK 30M (USD 2.9M). The proceeds will support the company's drug development activities, expand its preclinical pipeline and advance its lead therapeutic compounds towards clinical development. The round was led by the Dutch Investment Firm, Meneldor, who partnered with Norwegian and American investors. Among the Norwegian investors are Kistefos AS and Kvantia AS. Most of the earlier investors followed their seed investment, and the board chaired by Steven Powell, remains unchanged. "Hemispherian continues to accelerate its clinical ambitions and we are pleased to continue our support of Hemispherian's selective anti-cancer pharmaceutical pipeline. This funding will support preclinical development of GLIX1 and GLIX5, the company's lead assets." - Paul Lelieveld, Meneldor Co-Founder About Hemispherian AS Hemispherian is an innovative pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX). GLIX compounds target the TET2 enzyme and activate the DNA damage response resulting in cancer cell death. The company's lead compound, GLIX1, is in late-stage preclinical development for the treatment of glioblastoma multiforme, a deadly cancer of the central nervous system and the leading cause of death by disease in children. Hemispherian is further focused on developing a companion diagnostic tool to support patient selection for optimal therapeutic response to GLIX1. Hemispherian is based in Oslo, Norway. For more information, visit . About Meneldor Meneldor, based in the Netherlands, invests in early-stage Western European biotech and pharmaceutical companies. Meneldor is focussed on companies that develop new biological or chemical molecular entities, that address a significant unmet medical need. Hemispherian is Meneldor's sixth and most recent addition to their list of portfolio companies. About Kistefos Kistefos AS is a private investment company owned by Christen Sveaas. The company was established in 1998 and manages a diversified portfolio of companies within a variety of industries including offshore, shipping, financial services, technology and real estate. Kistefos' investment portfolio is managed from Oslo, Norway, and is mainly focused on investments in Europe. About Kvantia Kvantia is a global Investor Partnership in Oslo, Norway, formerly Andenæsgruppen. Kvantia has a disciplined investment strategy securing superior risk adjusted returns, while at the same time aiming for positive influence and impact on qualitative aspects of life on earth. Their quantitative activities are organized in Kvantia AS and their qualitative activities in Kvalia AS. Contact: Zeno Albisser, CEO Gaustadalléen 21 0349 Oslo [email protected] +47 406 03 455 Logo - SOURCE Hemispherian AS

OSLO, Norway, Oct. 19, 2022 /PRNewswire/ -- Hemispherian AS ("Hemispherian'' or the "Company"), a Norwegian preclinical pharmaceutical company focused on small molecule cancer therapeutics targeting the DNA damage response, is delighted to announce a successful European Innovation Council (EIC) Accelerator grant application. This grant will provide EUR 2.5M in grant funding and the jury recommends an additional EUR 7.5M in equity financing from the EIC fund. Financing from the EIC accelerator will be used to advance GLIX1, one of Hemispherian's lead assets, through a phase I and phase II clinical trial. "We are pleased to accept funding through the EIC accelerator program. This funding will ensure the successful development of Hemispherian's lead asset, GLIX1, through phase I and phase II clinical trials." - Adam Robertson, PhD, Chief Scientific Officer, Hemispherian About Hemispherian AS Hemispherian is an innovative pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX). GLIX compounds target the TET2 enzyme and activate the DNA damage response resulting in cancer cell death. The company's lead compound, GLIX1, is in late-stage preclinical development for the treatment of glioblastoma, a deadly cancer of the central nervous system and the leading cause of death by disease in children. Hemispherian is further developing a companion diagnostic tool to support patient selection for optimal therapeutic response to GLIX1. Hemispherian is based in Oslo, Norway. For more information, visit . About the EIC Accelerator The EIC accelerator is Europe's most prestigious and competitive grant for Small and medium-sized enterprises. In this round there were 986 applicants and 74 were funded. The applicant pool included 36 countries, with 21 countries having at least one successful applicant. The EIC accelerator provides funding as a grant and equity investment. The grant component is up to EUR 2.5M and the equity component provided by the EIC Fund is up to EUR 15M per project. Successful applicants must pass three independent review rounds – an initial screening round with 3 reviewers, a more rigorous paper based review with 4 different experts and finally the applicants are invited for an interview with 4-5 experts. All experts from the three review rounds must approve in order for the application to receive funding. Contact: Zeno Albisser, CEO Lørenveien73 0580 Oslo [email protected] +47 406 03 455 Logo - SOURCE Hemispherian AS